Is it true that ulcer medicine can overcome the symptoms of the Covid-19 corona virus? These are Expert Findings!

Suara.com – New research has found that some Covid-19 coronavirus patients improve more quickly than others after taking stomach pain medication.

Famotidine, better known as Pepcid is a common over-the-counter medication for heartburn. This drug is believed to be able to help relieve the symptoms of the Covid-19 corona virus.

Researchers have proven it in 55 people who have not been vaccinated and asked them to take a placebo or 80 milligrams of the heartburn medicine 3 times a day.

Researchers also took blood samples from each participant and asked them to undergo a nose swab test to detect the Covid-19 corona virus.

Also Read:
Is it true that the Omicron variant causes back pain? This is Expert Word!

The results of laboratory tests showed that the level of inflammation in people who took famotidine healed faster than people who took a placebo.

Medicine illustration (pexels)
Medicine illustration (pexels)

When compared with the placebo group, people taking famotidine also reported symptoms of the coronavirus, such as chest tightness, coughing and abdominal pain.

The researchers concluded that famotidine is safe and well tolerated in mild to moderate COVID-19 patients.

The study showed that famotidine could lead to earlier resolution of symptoms and inflammation without compromising anti-SARS-CoV-2 immunity. However, they argue that additional randomized trials are still needed.

Taking anti-heartburn drugs to treat the Covid-19 corona virus may not make sense. But, the relationship between the two is a little easier to see if you think about how drugs work to relieve heartburn.

Also Read:
Wow, Omicron Stealth BA.2 Increases Child Death Risk? These are Research Findings

Jamie Alan, professor of pharmacology and toxicology at Michigan State University Very Well Healthsays famotidine can help block a type of histamine receptor found in your stomach.

Tobias Janowitz, an assistant professor at the Cold Spring Harbor Laboratory, said previous research had shown that famotidine appears to decrease inflammation caused by the coronavirus, because it blocks certain molecular pathways.

Janowitz and colleagues decided to investigate the potential of Fanotidine in coronavirus patients, because there is evidence from retrospective studies and case series that Famotidine may have a moderate effect.

However, Janowitz also noted that the study results were not obtained from a randomized, placebo-controlled, double-blind trial.

Meanwhile, randomized, placebo-controlled and double-blind trials are the general standard for a study. Janowitz still wants to thoroughly study Famotidine.